This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 23, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of BioScrip, Inc. ("BioScrip" or the "Company") (NASDAQ: BIOS). Such investors are advised to contact
Robert S. Willoughby at
email@example.com or 888-476-6529, ext. 237.
The investigation concerns whether BioScrip and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On
September 23, 2013 the Company announced in an Securities and Exchange Commission, (SEC), Form 8-K filing, that it received a civil investigative demand issued by
the United States Attorney's Office for the Southern District of
New York and a subpoena from the
New York State Attorney General's Medicaid Fraud Control Unit, regarding the distribution of the Novartis Pharmaceuticals Corporation product Exjade(R) by the Company's legacy specialty pharmacy division.
On this news, shares of BioScrip fell
$0.82 per share to more than 7.41% on intraday trading to a price of
September 23, 2013.
The Pomerantz Firm, with offices in
San Diego and
Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late
Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See
CONTACT:Robert S. WilloughbyPomerantz Grossman Hufford Dahlstrom & Gross LLP
Pomerantz Grossman Hufford Dahlstrom & Gross LLP